Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Haematologica|October 6, 2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysisSilvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Annals of Hematology|September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working GroupGregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
The Lancet. Haematology|December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Annalisa Chiappella, Luca Nassi, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Hematological Oncology|May 2, 2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantationAndrés J M Ferreri, Marianna Sassone, Piera Angelillo, et al.
Cancer Medicine|April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experienceAnna Furlan, Michele Cea, Laura Pavan, et al.
Pageof 15